Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Understand the source comparison

Is Hexarelin Legal: Regulatory Comparison

The following table compares hexarelin's legal and regulatory status to related growth hormone compounds, clarifying where each stands in the FDA approval hierarchy and what that means for legal access. Hexarelin Not FDA-approved; investigational new drug Labo

No winner is assigned.

This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.

  • The following table compares hexarelin's legal and regulatory status to related growth hormone compounds, clarifying where each stands in the FDA approval hierarchy and what that means for legal access.
  • Hexarelin
  • Not FDA-approved; investigational new drug
  • Laboratory research only; not for human therapeutic use
  • Not scheduled
  • Potent GH secretagogue with documented pharmacology but no completed Phase III trials. Legally restricted to institutional research settings
  • Tesamorelin (Egrifta)
  • FDA-approved 2010 for HIV-associated lipodystrophy
  • Prescription therapy for approved indications; off-label use at prescriber discretion
  • Only FDA-approved GHRH analog; legal for therapeutic use when prescribed by licensed provider
  • Ipamorelin
  • Laboratory research only; compounded formulations sold under research exemption
  • Selective ghrelin receptor agonist with minimal cortisol/prolactin elevation; widely used in research but lacks therapeutic approval
  • Recombinant Human GH (rhGH)
  • FDA-approved for GHD, Turner syndrome, Prader-Willi, others
  • Prescription therapy for approved indications; highly regulated
  • Gold standard GH replacement therapy; illegal to prescribe for anti-aging or athletic enhancement outside approved indications
  • Sermorelin
  • Not FDA-approved as finished drug; approved as diagnostic agent (Geref)
  • Compounded formulations sold for off-label use; diagnostic formulation FDA-approved
  • GHRH(1-29) fragment; compounded versions occupy same legal gray area as hexarelin but more widely prescribed off-label
  • MK-677 (Ibutamoren)
  • Laboratory research only; frequently mislabeled as SARM
  • Oral GH secretagogue with 24-hour half-life; no FDA approval and significant regulatory scrutiny due to misbranding as supplement
  • The comparison reveals that hexarelin's legal status is not unique. Most peptide-based GH secretagogues exist in the same investigational category. The difference lies in enforcement: compounds marketed aggressively to consumers (like MK-677) face higher scrutiny than those sold strictly to research institutions.

Related resources

More comparisons